General
Preferred name
IRDABISANT
Synonyms
CEP-26401 ()
CEP 26401 ()
CEP26401 ()
IRDABISANT HYDROCHLORIDE ()
Cep 26401 ()
CEP26401 HYDROCHLORIDE ()
CEP-26401 hydrochloride ()
P&D ID
PD058379
CAS
1005402-19-6
Tags
available
drug candidate
Drug indication
Cognitive impairment
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Irdabisant (CEP-26401) is a selective, orally active and blood-brain barrier (BBB) penetrant histamine H3 receptor (H3R) inverse agonist/inverse agonist with Ki values of 7.2 nM and 2.0 nM for rat H3R and human H3R, respectively. Irdabisant has relatively low inhibitory activity against hERG current with an IC50 of 13.8 ¦ÌM. Irdabisant has cognition-enhancing and wake-promoting activities in the rat social recognition model. Irdabisant can be used to research schizophrenia or cognitive impairment[1][2].
PRICE 151
DESCRIPTION Irdabisant (CEP-26401) (CEP-26401) is a selective, orally active and blood-brain barrier (BBB) penetrant antagonist/inverse agonist of histamine H3 receptor (H3R) (rat H3R Ki= 7.2 nM, human H3R Ki= 2.0 nM). Irdabisant exhibits relatively low inhibitory activity against hERG current (IC50= 13.8 ??M). Irdabisant exhibits cognition-enhancing and wake-promoting activities in the rat social recognition model. Irdabisant can be used for research on schizophrenia or cognitive impairment.
DESCRIPTION Irdabisant is a potent, selective histamine H3 receptor inverse agonist. It displayed potent antagonist and inverse agonist activities in [³⁵S]guanosine 5'-O-(γ-thio)triphosphate binding assays. It may also have therapeutic utility in treating schizophrenia or be used as adjunctive therapy to approved antipsychotics. (BOC Sciences Bioactive Compounds)
DESCRIPTION Irdabisant (CEP-26401) (CEP-26401) is a selective, orally active and blood-brain barrier (BBB) penetrant antagonist/inverse agonist of histamine H3 receptor (H3R) (rat H3R Ki= 7.2 nM, human H3R Ki= 2.0 nM). Irdabisant exhibits relatively low inhibitory activity against hERG current (IC50= 13.8 μM). Irdabisant exhibits cognition-enhancing and wake-promoting activities in the rat social recognition model. Irdabisant can be used for research on schizophrenia or cognitive impairment. (TargetMol Bioactive Compound Library)
Compound Sets
8
BOC Sciences Bioactive Compounds
irdabisant-cas-1005402-19-6-item-474945
ChEMBL Drugs
CHEMBL1829335
CHEMBL1813067
DrugBank
DB12900
DrugMAP
DMR3E4L
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1829335
MedChem Express Bioactive Compound Library
HY-109968
ReFrame library
TargetMol Bioactive Compound Library
T32191
External IDs
27
Properties
(calculated by RDKit )
Molecular Weight
313.18
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
2
cLogP
2.69
TPSA
58.22
Fraction CSP3
0.44
Chiral centers
1.0
Largest ring
6.0
QED
0.83
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Immunology/Inflammation
Neuroscience
Neuronal Signaling
Solubility
10 mM in DMSO
Target
Histamine Receptor
H3 receptor
Source data